Cerebrospinal fluid monoamine levels in central disorders of hypersomnolence
Abstract Study Objectives Whether the cause of daytime sleepiness in narcolepsy type 1 (NT1) is a direct consequence of the loss of orexin (ORX) neurons or whether low orexin reduces the efficacy of the monoaminergic systems to promote wakefulness is unclear. The neurobiology underlying sleepiness i...
Saved in:
| Published in | Sleep (New York, N.Y.) Vol. 44; no. 7; p. 1 |
|---|---|
| Main Authors | , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
US
Oxford University Press
01.07.2021
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Abstract
Study Objectives
Whether the cause of daytime sleepiness in narcolepsy type 1 (NT1) is a direct consequence of the loss of orexin (ORX) neurons or whether low orexin reduces the efficacy of the monoaminergic systems to promote wakefulness is unclear. The neurobiology underlying sleepiness in other central hypersomnolence disorders, narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH), is currently unknown.
Methods
Eleven biogenic amines including the monoaminergic neurotransmitters and their metabolites and five trace amines were measured in the cerebrospinal fluid (CSF) of 94 drug-free subjects evaluated at the French National Reference Center for Narcolepsy: 39 NT1(orexin-deficient) patients, 31 patients with objective sleepiness non orexin-deficient (NT2 and IH), and 24 patients without objective sleepiness.
Results
Three trace amines were undetectable in the sample: tryptamine, octopamine, and 3-iodothyronamine. No significant differences were found among the three groups for quantified monoamines and their metabolites in crude and adjusted models; however, CSF 5-hydroxyindoleacetic acid (5-HIAA) levels tended to increase in NT1 compared to other patients after adjustment. Most of the biomarkers were not associated with ORX-A levels, clinical or neurophysiological parameters, but a few biomarkers (e.g. 3-methoxy-4-hydroxyphenylglycol and norepinephrine) correlated with daytime sleepiness and high rapid eye movement (REM) sleep propensity.
Conclusions
We found no striking differences among CSF monoamines, their metabolites and trace amine levels, and few associations between them and key clinical or neurophysiological parameters in NT1, NT2/IH, and patients without objective sleepiness. Although mostly negative, these findings are a significant contribution to our understanding of the neurobiology of hypersomnolence in these disorders that remain mysterious and deserve further exploration. |
|---|---|
| AbstractList | Study Objectives: Whether the cause of daytime sleepiness in narcolepsy type 1 (NT1) is a direct consequence of the loss of orexin (ORX) neurons or whether low orexin reduces the efficacy of the monoaminergic systems to promote wakefulness is unclear. The neurobiology underlying sleepiness in other central hypersomnolence disorders, narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH), is currently unknown. Methods: Eleven biogenic amines including the monoaminergic neurotransmitters and their metabolites and five trace amines were measured in the cerebrospinal fluid (CSF) of 94 drug-free subjects evaluated at the French National Reference Center for Narcolepsy: 39 NT1(orexin-deficient) patients, 31 patients with objective sleepiness non orexin-deficient (NT2 and IH), and 24 patients without objective sleepiness. Results: Three trace amines were undetectable in the sample: tryptamine, octopamine, and 3-iodothyronamine. No significant differences were found among the three groups for quantified monoamines and their metabolites in crude and adjusted models; however, CSF 5-hydroxyindoleacetic acid (5-HIAA) levels tended to increase in NT1 compared to other patients after adjustment. Most of the biomarkers were not associated with ORX-A levels, clinical or neurophysiological parameters, but a few biomarkers (e.g. 3-methoxy-4-hydroxyphenylglycol and norepinephrine) correlated with daytime sleepiness and high rapid eye movement (REM) sleep propensity. Conclusions: We found no striking differences among CSF monoamines, their metabolites and trace amine levels, and few associations between them and key clinical or neurophysiological parameters in NT1, NT2/IH, and patients without objective sleepiness. Although mostly negative, these findings are a significant contribution to our understanding of the neurobiology of hypersomnolence in these disorders that remain mysterious and deserve further exploration. Key words: central disorders of hypersomnolence; narcolepsy; hypersomnia; sleepiness; cerebrospinal fluid; monoamine; hypocretin/orexin Whether the cause of daytime sleepiness in narcolepsy type 1 (NT1) is a direct consequence of the loss of orexin (ORX) neurons or whether low orexin reduces the efficacy of the monoaminergic systems to promote wakefulness is unclear. The neurobiology underlying sleepiness in other central hypersomnolence disorders, narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH), is currently unknown. Eleven biogenic amines including the monoaminergic neurotransmitters and their metabolites and five trace amines were measured in the cerebrospinal fluid (CSF) of 94 drug-free subjects evaluated at the French National Reference Center for Narcolepsy: 39 NT1(orexin-deficient) patients, 31 patients with objective sleepiness non orexin-deficient (NT2 and IH), and 24 patients without objective sleepiness. Three trace amines were undetectable in the sample: tryptamine, octopamine, and 3-iodothyronamine. No significant differences were found among the three groups for quantified monoamines and their metabolites in crude and adjusted models; however, CSF 5-hydroxyindoleacetic acid (5-HIAA) levels tended to increase in NT1 compared to other patients after adjustment. Most of the biomarkers were not associated with ORX-A levels, clinical or neurophysiological parameters, but a few biomarkers (e.g. 3-methoxy-4-hydroxyphenylglycol and norepinephrine) correlated with daytime sleepiness and high rapid eye movement (REM) sleep propensity. We found no striking differences among CSF monoamines, their metabolites and trace amine levels, and few associations between them and key clinical or neurophysiological parameters in NT1, NT2/IH, and patients without objective sleepiness. Although mostly negative, these findings are a significant contribution to our understanding of the neurobiology of hypersomnolence in these disorders that remain mysterious and deserve further exploration. Abstract Study Objectives Whether the cause of daytime sleepiness in narcolepsy type 1 (NT1) is a direct consequence of the loss of orexin (ORX) neurons or whether low orexin reduces the efficacy of the monoaminergic systems to promote wakefulness is unclear. The neurobiology underlying sleepiness in other central hypersomnolence disorders, narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH), is currently unknown. Methods Eleven biogenic amines including the monoaminergic neurotransmitters and their metabolites and five trace amines were measured in the cerebrospinal fluid (CSF) of 94 drug-free subjects evaluated at the French National Reference Center for Narcolepsy: 39 NT1(orexin-deficient) patients, 31 patients with objective sleepiness non orexin-deficient (NT2 and IH), and 24 patients without objective sleepiness. Results Three trace amines were undetectable in the sample: tryptamine, octopamine, and 3-iodothyronamine. No significant differences were found among the three groups for quantified monoamines and their metabolites in crude and adjusted models; however, CSF 5-hydroxyindoleacetic acid (5-HIAA) levels tended to increase in NT1 compared to other patients after adjustment. Most of the biomarkers were not associated with ORX-A levels, clinical or neurophysiological parameters, but a few biomarkers (e.g. 3-methoxy-4-hydroxyphenylglycol and norepinephrine) correlated with daytime sleepiness and high rapid eye movement (REM) sleep propensity. Conclusions We found no striking differences among CSF monoamines, their metabolites and trace amine levels, and few associations between them and key clinical or neurophysiological parameters in NT1, NT2/IH, and patients without objective sleepiness. Although mostly negative, these findings are a significant contribution to our understanding of the neurobiology of hypersomnolence in these disorders that remain mysterious and deserve further exploration. Study Objectives Whether the cause of daytime sleepiness in narcolepsy type 1 (NT1) is a direct consequence of the loss of orexin (ORX) neurons or whether low orexin reduces the efficacy of the monoaminergic systems to promote wakefulness is unclear. The neurobiology underlying sleepiness in other central hypersomnolence disorders, narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH), is currently unknown. Methods Eleven biogenic amines including the monoaminergic neurotransmitters and their metabolites and five trace amines were measured in the cerebrospinal fluid (CSF) of 94 drug-free subjects evaluated at the French National Reference Center for Narcolepsy: 39 NT1(orexin-deficient) patients, 31 patients with objective sleepiness non orexin-deficient (NT2 and IH), and 24 patients without objective sleepiness. Results Three trace amines were undetectable in the sample: tryptamine, octopamine, and 3-iodothyronamine. No significant differences were found among the three groups for quantified monoamines and their metabolites in crude and adjusted models; however, CSF 5-hydroxyindoleacetic acid (5-HIAA) levels tended to increase in NT1 compared to other patients after adjustment. Most of the biomarkers were not associated with ORX-A levels, clinical or neurophysiological parameters, but a few biomarkers (e.g. 3-methoxy-4-hydroxyphenylglycol and norepinephrine) correlated with daytime sleepiness and high rapid eye movement (REM) sleep propensity. Conclusions We found no striking differences among CSF monoamines, their metabolites and trace amine levels, and few associations between them and key clinical or neurophysiological parameters in NT1, NT2/IH, and patients without objective sleepiness. Although mostly negative, these findings are a significant contribution to our understanding of the neurobiology of hypersomnolence in these disorders that remain mysterious and deserve further exploration. Abstract Study Objectives Whether the cause of daytime sleepiness in narcolepsy type 1 (NT1) is a direct consequence of the loss of orexin (ORX) neurons or whether low orexin reduces the efficacy of the monoaminergic systems to promote wakefulness is unclear. The neurobiology underlying sleepiness in other central hypersomnolence disorders, narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH), is currently unknown. Methods Eleven biogenic amines including the monoaminergic neurotransmitters and their metabolites and five trace amines were measured in the cerebrospinal fluid (CSF) of 94 drug-free subjects evaluated at the French National Reference Center for Narcolepsy: 39 NT1(orexin-deficient) patients, 31 patients with objective sleepiness non orexin-deficient (NT2 and IH), and 24 patients without objective sleepiness. Results Three trace amines were undetectable in the sample: tryptamine, octopamine, and 3-iodothyronamine. No significant differences were found among the three groups for quantified monoamines and their metabolites in crude and adjusted models; however, CSF 5-hydroxyindoleacetic acid (5-HIAA) levels tended to increase in NT1 compared to other patients after adjustment. Most of the biomarkers were not associated with ORX-A levels, clinical or neurophysiological parameters, but a few biomarkers (e.g. 3-methoxy-4-hydroxyphenylglycol and norepinephrine) correlated with daytime sleepiness and high rapid eye movement (REM) sleep propensity. Conclusions We found no striking differences among CSF monoamines, their metabolites and trace amine levels, and few associations between them and key clinical or neurophysiological parameters in NT1, NT2/IH, and patients without objective sleepiness. Although mostly negative, these findings are a significant contribution to our understanding of the neurobiology of hypersomnolence in these disorders that remain mysterious and deserve further exploration. Whether the cause of daytime sleepiness in narcolepsy type 1 (NT1) is a direct consequence of the loss of orexin (ORX) neurons or whether low orexin reduces the efficacy of the monoaminergic systems to promote wakefulness is unclear. The neurobiology underlying sleepiness in other central hypersomnolence disorders, narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH), is currently unknown.STUDY OBJECTIVESWhether the cause of daytime sleepiness in narcolepsy type 1 (NT1) is a direct consequence of the loss of orexin (ORX) neurons or whether low orexin reduces the efficacy of the monoaminergic systems to promote wakefulness is unclear. The neurobiology underlying sleepiness in other central hypersomnolence disorders, narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH), is currently unknown.Eleven biogenic amines including the monoaminergic neurotransmitters and their metabolites and five trace amines were measured in the cerebrospinal fluid (CSF) of 94 drug-free subjects evaluated at the French National Reference Center for Narcolepsy: 39 NT1(orexin-deficient) patients, 31 patients with objective sleepiness non orexin-deficient (NT2 and IH), and 24 patients without objective sleepiness.METHODSEleven biogenic amines including the monoaminergic neurotransmitters and their metabolites and five trace amines were measured in the cerebrospinal fluid (CSF) of 94 drug-free subjects evaluated at the French National Reference Center for Narcolepsy: 39 NT1(orexin-deficient) patients, 31 patients with objective sleepiness non orexin-deficient (NT2 and IH), and 24 patients without objective sleepiness.Three trace amines were undetectable in the sample: tryptamine, octopamine, and 3-iodothyronamine. No significant differences were found among the three groups for quantified monoamines and their metabolites in crude and adjusted models; however, CSF 5-hydroxyindoleacetic acid (5-HIAA) levels tended to increase in NT1 compared to other patients after adjustment. Most of the biomarkers were not associated with ORX-A levels, clinical or neurophysiological parameters, but a few biomarkers (e.g. 3-methoxy-4-hydroxyphenylglycol and norepinephrine) correlated with daytime sleepiness and high rapid eye movement (REM) sleep propensity.RESULTSThree trace amines were undetectable in the sample: tryptamine, octopamine, and 3-iodothyronamine. No significant differences were found among the three groups for quantified monoamines and their metabolites in crude and adjusted models; however, CSF 5-hydroxyindoleacetic acid (5-HIAA) levels tended to increase in NT1 compared to other patients after adjustment. Most of the biomarkers were not associated with ORX-A levels, clinical or neurophysiological parameters, but a few biomarkers (e.g. 3-methoxy-4-hydroxyphenylglycol and norepinephrine) correlated with daytime sleepiness and high rapid eye movement (REM) sleep propensity.We found no striking differences among CSF monoamines, their metabolites and trace amine levels, and few associations between them and key clinical or neurophysiological parameters in NT1, NT2/IH, and patients without objective sleepiness. Although mostly negative, these findings are a significant contribution to our understanding of the neurobiology of hypersomnolence in these disorders that remain mysterious and deserve further exploration.CONCLUSIONSWe found no striking differences among CSF monoamines, their metabolites and trace amine levels, and few associations between them and key clinical or neurophysiological parameters in NT1, NT2/IH, and patients without objective sleepiness. Although mostly negative, these findings are a significant contribution to our understanding of the neurobiology of hypersomnolence in these disorders that remain mysterious and deserve further exploration. Study Objectives: Whether the cause of daytime sleepiness in narcolepsy type 1 (NT1) is a direct consequence of the loss of orexin (ORX) neurons or whether low orexin reduces the efficacy of the monoaminergic systems to promote wakefulness is unclear. The neurobiology underlying sleepiness in other central hypersomnolence disorders, narcolepsy type 2 (NT2), and idiopathic hypersomnia (IH), is currently unknown. |
| Audience | Academic |
| Author | Roeser, Julien Dauvilliers, Yves Jaussent, Isabelle Ciardiello, Claudio Kilduff, Thomas S Barateau, Lucie |
| AuthorAffiliation | 3 INM, University of Montpellier, INSERM , Montpellier , France 1 Sleep–Wake Disorders Unit, Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier, University of Montpellier , Montpellier , France 4 Charles River Laboratories, South San Francisco , San Francisco, CA , USA 5 Center for Neuroscience, Biosciences Division, SRI International , Menlo Park, CA , USA 2 National Reference Network for Narcolepsy, CHU Montpellier , Montpellier , France |
| AuthorAffiliation_xml | – name: 2 National Reference Network for Narcolepsy, CHU Montpellier , Montpellier , France – name: 3 INM, University of Montpellier, INSERM , Montpellier , France – name: 1 Sleep–Wake Disorders Unit, Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier, University of Montpellier , Montpellier , France – name: 5 Center for Neuroscience, Biosciences Division, SRI International , Menlo Park, CA , USA – name: 4 Charles River Laboratories, South San Francisco , San Francisco, CA , USA |
| Author_xml | – sequence: 1 givenname: Lucie surname: Barateau fullname: Barateau, Lucie organization: Sleep–Wake Disorders Unit, Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier, University of Montpellier, Montpellier, France – sequence: 2 givenname: Isabelle orcidid: 0000-0002-8205-7590 surname: Jaussent fullname: Jaussent, Isabelle organization: INM, University of Montpellier, INSERM, Montpellier, France – sequence: 3 givenname: Julien surname: Roeser fullname: Roeser, Julien organization: Charles River Laboratories, South San Francisco, San Francisco, CA, USA – sequence: 4 givenname: Claudio surname: Ciardiello fullname: Ciardiello, Claudio organization: Charles River Laboratories, South San Francisco, San Francisco, CA, USA – sequence: 5 givenname: Thomas S orcidid: 0000-0002-6823-0094 surname: Kilduff fullname: Kilduff, Thomas S organization: Center for Neuroscience, Biosciences Division, SRI International, Menlo Park, CA, USA – sequence: 6 givenname: Yves orcidid: 0000-0003-0683-6506 surname: Dauvilliers fullname: Dauvilliers, Yves email: ydauvilliers@yahoo.fr organization: Sleep–Wake Disorders Unit, Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier, University of Montpellier, Montpellier, France |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33476396$$D View this record in MEDLINE/PubMed https://hal.science/hal-03665210$$DView record in HAL |
| BookMark | eNqFkk1v1DAQhi1URLeFI1cUiQsc0vojdpIL0moFFGklLnC2HHvcdeXYIU5WKr8eh90CXYGQD_aMn3k9npkLdBZiAIReEnxFcMuukwcYrr8n1WFCn6AV4RyXbb46QytMBCkbgvk5ukjpDme7atkzdM5YVQvWihXabmCEboxpcEH5wvrZmaKPIareBSg87MGnwoVCQ5jGTBiX4mhgTEW0xe5-yKfYh-ghaHiOnlrlE7w47pfo64f3XzY35fbzx0-b9bbUgvCpZJoI2hisMefAuqoCLYyqhDEtUTpb1natrTqljAUiFK2oAWOtaIF0WlXsEr076A5z14M5piaH0fVqvJdROfn4JridvI172dCaEFpngbcHgd1J2M16KxcfZkJwSvCeZPbN8bExfpshTbJ3SYP3KkCck6RVg2nNK8Iz-voEvYvzmOuaKc5ryloq2t_UrfIgXbAx56gXUbmuc4-aRtSL1tVfqLwM9E7nGbAu-x8FvPqzKL--9dDrDLADoHO70whWajepycWlRs5LguUyUfLnRMnjROWo8iTqQfhf_LFccR7-g_4Arsfeww |
| CitedBy_id | crossref_primary_10_1093_sleep_zsad323 crossref_primary_10_1111_jsr_14146 crossref_primary_10_1016_j_neucli_2023_102934 crossref_primary_10_1007_s12640_021_00411_4 crossref_primary_10_1111_jsr_13631 crossref_primary_10_1007_s40675_023_00249_6 crossref_primary_10_1016_j_smrv_2021_101546 crossref_primary_10_1016_j_smrv_2023_101766 crossref_primary_10_1016_S0140_6736_22_01018_2 crossref_primary_10_1016_j_neurol_2023_08_001 crossref_primary_10_1093_sleepadvances_zpae059 crossref_primary_10_1021_acs_jpclett_2c00737 crossref_primary_10_1016_j_smrv_2022_101709 crossref_primary_10_1111_bpa_13027 crossref_primary_10_5650_jos_ess23062 crossref_primary_10_1016_j_bpsgos_2024_100445 crossref_primary_10_2147_NSS_S279345 |
| Cites_doi | 10.1124/jpet.107.132647 10.1126/scitranslmed.3004685 10.1016/j.biopsych.2016.10.012 10.1016/S0896-6273(00)00058-1 10.1002/ana.410130306 10.1016/j.conb.2017.03.021 10.1124/pr.117.015305 10.1172/JCI71017 10.1093/sleep/zsaa095 10.1093/sleep/32.2.181 10.1016/0024-3205(85)90242-5 10.1093/sleep/9.1.246 10.1016/j.neuron.2017.01.014 10.5665/sleep.2114 10.1016/j.smrv.2010.11.003 10.1038/79690 10.1212/WNL.32.11.1299 10.1016/S0895-4356(00)00314-0 10.5664/jcsm.2922 10.1093/sleep/zsx164 10.1097/00001756-200302100-00015 10.1016/S0092-8674(00)81973-X 10.1002/ana.24710 10.1016/j.biopsych.2012.05.014 10.1111/j.1365-2869.2010.00819.x 10.1016/S0092-8674(00)80949-6 10.1093/sleep/14.6.540 10.1038/s41386-019-0386-8 10.1016/S0896-6273(01)00293-8 10.1093/sleep/32.2.175 10.1038/s41583-018-0097-x 10.1038/nrneurol.2015.172 10.1038/npp.2016.216 10.1073/pnas.95.1.322 10.1016/j.smrv.2020.101326 10.1002/ana.25141 10.1038/mp.2012.57 10.1523/JNEUROSCI.0073-14.2014 10.1016/j.smrv.2018.09.006 |
| ContentType | Journal Article |
| Copyright | The Author(s) 2021. Published by Oxford University Press on behalf of Sleep Research Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2021 Sleep Research Society 2021. Published by Oxford University Press on behalf of the Sleep Research Society. All rights reserved. For permissions, please email: journals.permissions@oup.com. COPYRIGHT 2021 Oxford University Press The Author(s) 2021. Published by Oxford University Press on behalf of Sleep Research Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com Distributed under a Creative Commons Attribution 4.0 International License |
| Copyright_xml | – notice: The Author(s) 2021. Published by Oxford University Press on behalf of Sleep Research Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com 2021 – notice: Sleep Research Society 2021. Published by Oxford University Press on behalf of the Sleep Research Society. All rights reserved. For permissions, please email: journals.permissions@oup.com. – notice: COPYRIGHT 2021 Oxford University Press – notice: The Author(s) 2021. Published by Oxford University Press on behalf of Sleep Research Society. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com – notice: Distributed under a Creative Commons Attribution 4.0 International License |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 3V. 7X7 7XB 88E 88G 8FI 8FJ 8FK 8G5 ABUWG AFKRA AZQEC BENPR CCPQU DWQXO FYUFA GHDGH GNUQQ GUQSH K9. M0S M1P M2M M2O MBDVC PHGZM PHGZT PJZUB PKEHL PPXIY PQEST PQQKQ PQUKI PRINS PSYQQ Q9U 7X8 1XC 5PM |
| DOI | 10.1093/sleep/zsab012 |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed ProQuest Central (Corporate) Health & Medical Collection ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) Psychology Database (Alumni) ProQuest Hospital Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Research Library ProQuest Central (Alumni) ProQuest Central UK/Ireland ProQuest Central Essentials ProQuest Central ProQuest One ProQuest Central Korea Health Research Premium Collection Health Research Premium Collection (Alumni) ProQuest Central Student ProQuest Research Library ProQuest Health & Medical Complete (Alumni) ProQuest Health & Medical Collection Proquest Medical Database Psychology Database Research Library Research Library (Corporate) ProQuest Central Premium ProQuest One Academic ProQuest Health & Medical Research Collection ProQuest One Academic Middle East (New) ProQuest One Health & Nursing ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China ProQuest One Psychology ProQuest Central Basic MEDLINE - Academic Hyper Article en Ligne (HAL) PubMed Central (Full Participant titles) |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) ProQuest One Psychology Research Library Prep ProQuest Central Student ProQuest One Academic Middle East (New) ProQuest Central Essentials ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest One Health & Nursing Research Library (Alumni Edition) ProQuest Central China ProQuest Central ProQuest Health & Medical Research Collection Health Research Premium Collection Health and Medicine Complete (Alumni Edition) ProQuest Central Korea Health & Medical Research Collection ProQuest Research Library ProQuest Central (New) ProQuest Medical Library (Alumni) ProQuest Central Basic ProQuest One Academic Eastern Edition ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Psychology Journals (Alumni) ProQuest Hospital Collection (Alumni) ProQuest Health & Medical Complete ProQuest Medical Library ProQuest Psychology Journals ProQuest One Academic UKI Edition ProQuest One Academic ProQuest One Academic (New) ProQuest Central (Alumni) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE ProQuest One Psychology MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 3 dbid: BENPR name: ProQuest Central url: https://www.proquest.com/central sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology |
| EISSN | 1550-9109 |
| ExternalDocumentID | PMC8271127 oai_HAL_hal_03665210v1 A700188675 33476396 10_1093_sleep_zsab012 10.1093/sleep/zsab012 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GeographicLocations | France United States |
| GeographicLocations_xml | – name: France – name: United States |
| GrantInformation_xml | – fundername: NINDS NIH HHS grantid: R01 NS098813 – fundername: NINDS NIH HHS grantid: R01 NS103529 – fundername: ; grantid: R01 NS103529; R01 NS098813 – fundername: ; grantid: R14066FF |
| GroupedDBID | --- -DZ -ET ..I .55 .GJ 0R~ 123 1TH 2WC 48X 53G 5RE 5WD 6PF 7X7 88E 8FI 8FJ 8G5 AABZA AACZT AAJQQ AAPQZ AAPXW AARHZ AAUAY AAUQX AAVAP AAWTL ABDFA ABEJV ABGNP ABJNI ABLJU ABNHQ ABPTD ABQNK ABUWG ABVGC ABXVV ACFRR ACGFS ACUTJ ACVCV ACYHN ADBBV ADGZP ADHKW ADIPN ADQBN ADRTK ADVEK AEMDU AEMQT AENEX AENZO AETBJ AEWNT AFFNX AFFZL AFKRA AFOFC AFXAL AGINJ AGMDO AGUTN AHMBA AHMMS AJEEA AJNCP ALIPV ALMA_UNASSIGNED_HOLDINGS ALXQX APIBT APJGH AQKUS ATGXG AZQEC BAWUL BAYMD BCRHZ BENPR BEYMZ BPHCQ BTRTY BVXVI C45 CCPQU CDBKE DAKXR DIK DWQXO E3Z EBS EJD ENERS F5P FECEO FLUFQ FOEOM FOTVD FYUFA GAUVT GJXCC GNUQQ GUQSH H13 HMCUK IAO IHR ITC J5H JXSIZ KBUDW KOP KSI KSN M1P M2M M2O MBLQV MHKGH MVM NOMLY NOYVH O9- OAUYM OCZFY ODMLO OJZSN OK1 OPAEJ OVD OWPYF P2P PAFKI PEELM PHGZT PQQKQ PROAC PSQYO PSYQQ ROX ROZ RUSNO SJN TEORI TJX TR2 TWZ UKHRP WOQ X7M YAYTL YKOAZ YXANX ZGI ZXP AAYXX AGORE AHGBF AJBYB CITATION NU- PHGZM CGR CUY CVF ECM EIF NPM PMFND 3V. 7XB 8FK K9. MBDVC PJZUB PKEHL PPXIY PQEST PQUKI PRINS Q9U 7X8 1XC UMC 5PM |
| ID | FETCH-LOGICAL-c615t-3c1628d0c055e3b44ec6da46dd91ac4ecffb9f4baadfe16a242dedff69e1bca43 |
| IEDL.DBID | 7X7 |
| ISSN | 0161-8105 1550-9109 |
| IngestDate | Thu Aug 21 14:04:58 EDT 2025 Fri May 09 12:08:26 EDT 2025 Fri Jul 11 07:16:00 EDT 2025 Fri Jul 25 23:06:53 EDT 2025 Tue Jun 17 21:01:22 EDT 2025 Tue Jun 10 20:35:27 EDT 2025 Thu Apr 03 07:00:49 EDT 2025 Tue Jul 01 01:31:14 EDT 2025 Thu Apr 24 22:54:31 EDT 2025 Wed Apr 02 07:03:57 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 7 |
| Keywords | central disorders of hypersomnolence narcolepsy monoamine cerebrospinal fluid hypersomnia hypocretin/orexin sleepiness |
| Language | English |
| License | This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model Sleep Research Society 2021. Published by Oxford University Press on behalf of the Sleep Research Society. All rights reserved. For permissions, please email: journals.permissions@oup.com. Distributed under a Creative Commons Attribution 4.0 International License: http://creativecommons.org/licenses/by/4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c615t-3c1628d0c055e3b44ec6da46dd91ac4ecffb9f4baadfe16a242dedff69e1bca43 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 PMCID: PMC8271127 |
| ORCID | 0000-0002-8205-7590 0000-0003-0683-6506 0000-0002-6823-0094 0000-0002-6620-5127 |
| OpenAccessLink | https://academic.oup.com/sleep/article-pdf/44/7/zsab012/38890210/zsab012.pdf |
| PMID | 33476396 |
| PQID | 2557239269 |
| PQPubID | 2046369 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_8271127 hal_primary_oai_HAL_hal_03665210v1 proquest_miscellaneous_2480275415 proquest_journals_2557239269 gale_infotracmisc_A700188675 gale_infotracacademiconefile_A700188675 pubmed_primary_33476396 crossref_citationtrail_10_1093_sleep_zsab012 crossref_primary_10_1093_sleep_zsab012 oup_primary_10_1093_sleep_zsab012 |
| ProviderPackageCode | CITATION AAYXX |
| PublicationCentury | 2000 |
| PublicationDate | 2021-07-01 |
| PublicationDateYYYYMMDD | 2021-07-01 |
| PublicationDate_xml | – month: 07 year: 2021 text: 2021-07-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | US |
| PublicationPlace_xml | – name: US – name: United States – name: Westchester |
| PublicationTitle | Sleep (New York, N.Y.) |
| PublicationTitleAlternate | Sleep |
| PublicationYear | 2021 |
| Publisher | Oxford University Press |
| Publisher_xml | – name: Oxford University Press |
| References | Evangelista (2022080922480599000_CIT0026) 2018; 83 Bassetti (2022080922480599000_CIT0013) 2010; 19 de Lecea (2022080922480599000_CIT0001) 1998; 95 Tabuchi (2022080922480599000_CIT0007) 2014; 34 Rye (2022080922480599000_CIT0019) 2012; 4 Revel (2022080922480599000_CIT0022) 2013; 18 Szabo (2022080922480599000_CIT0039) 2019; 43 Tisdale (2022080922480599000_CIT0008) 2020 Lammers (2022080922480599000_CIT0036) 2020; 52 Shimada (2022080922480599000_CIT0015) 2020; 43 Lindemann (2022080922480599000_CIT0020) 2008; 324 Peyron (2022080922480599000_CIT0003) 2000; 6 Iber (2022080922480599000_CIT0024) Scammell (2022080922480599000_CIT0028) 2017; 93 Monti (2022080922480599000_CIT0037) 2011; 15 Dauvilliers (2022080922480599000_CIT0018) 2016; 80 Hasegawa (2022080922480599000_CIT0041) 2014; 124 Sakurai (2022080922480599000_CIT0002) 1998; 92 Lopez (2022080922480599000_CIT0043) 2017; 40 Faull (2022080922480599000_CIT0012) 1986; 9 Johns (2022080922480599000_CIT0023) 1991; 14 Schwartz (2022080922480599000_CIT0033) 2017; 42 Revel (2022080922480599000_CIT0021) 2012; 72 Thannickal (2022080922480599000_CIT0004) 2000; 27 Kanbayashi (2022080922480599000_CIT0016) 2009; 32 Mahoney (2022080922480599000_CIT0030) 2019; 20 Chemelli (2022080922480599000_CIT0005) 1999; 98 AASM: American Academy of Sleep Medicine (2022080922480599000_CIT0025) 2014 Faull (2022080922480599000_CIT0011) 1983; 13 Stanley (2022080922480599000_CIT0029) 1985; 37 Black (2022080922480599000_CIT0035) 2017; 82 Saper (2022080922480599000_CIT0009) 2017; 44 Trotti (2022080922480599000_CIT0042) 2013; 9 Dauvilliers (2022080922480599000_CIT0014) 2012; 35 Hara (2022080922480599000_CIT0006) 2001; 30 Montplaisir (2022080922480599000_CIT0010) 1982; 32 Ng (2022080922480599000_CIT0031) 2015; 11 Roth (2022080922480599000_CIT0040) 2013; 9 Nishino (2022080922480599000_CIT0017) 2009; 32 Bender (2022080922480599000_CIT0027) 2001; 54 Goonawardena (2022080922480599000_CIT0034) 2019; 44 Wisor (2022080922480599000_CIT0038) 2003; 14 Gainetdinov (2022080922480599000_CIT0032) 2018; 70 |
| References_xml | – volume: 324 start-page: 948 issue: 3 year: 2008 ident: 2022080922480599000_CIT0020 article-title: Trace amine-associated receptor 1 modulates dopaminergic activity publication-title: J Pharmacol Exp Ther. doi: 10.1124/jpet.107.132647 – volume: 4 start-page: 161ra151 issue: 161 year: 2012 ident: 2022080922480599000_CIT0019 article-title: Modulation of vigilance in the primary hypersomnias by endogenous enhancement of GABAA receptors publication-title: Sci Transl Med. doi: 10.1126/scitranslmed.3004685 – volume: 82 start-page: 623 issue: 9 year: 2017 ident: 2022080922480599000_CIT0035 article-title: Trace amine-associated receptor 1 agonists as narcolepsy therapeutics publication-title: Biol Psychiatry. doi: 10.1016/j.biopsych.2016.10.012 – volume: 27 start-page: 469 issue: 3 year: 2000 ident: 2022080922480599000_CIT0004 article-title: Reduced number of hypocretin neurons in human narcolepsy publication-title: Neuron. doi: 10.1016/S0896-6273(00)00058-1 – volume: 13 start-page: 258 issue: 3 year: 1983 ident: 2022080922480599000_CIT0011 article-title: Cerebrospinal fluid monoamine metabolites in narcolepsy and hypersomnia publication-title: Ann Neurol. doi: 10.1002/ana.410130306 – volume: 44 start-page: 186 year: 2017 ident: 2022080922480599000_CIT0009 article-title: Wake-sleep circuitry: an overview publication-title: Curr Opin Neurobiol. doi: 10.1016/j.conb.2017.03.021 – volume: 70 start-page: 549 issue: 3 year: 2018 ident: 2022080922480599000_CIT0032 article-title: Trace amines and their receptors publication-title: Pharmacol Rev. doi: 10.1124/pr.117.015305 – year: 2020 ident: 2022080922480599000_CIT0008 article-title: Animal models of narcolepsy and the hypocretin/orexin system: past, present, and future publication-title: Sleep. – volume: 124 start-page: 604 issue: 2 year: 2014 ident: 2022080922480599000_CIT0041 article-title: Orexin neurons suppress narcolepsy via 2 distinct efferent pathways publication-title: J Clin Invest. doi: 10.1172/JCI71017 – volume: 43 issue: 11 year: 2020 ident: 2022080922480599000_CIT0015 article-title: Metabolome analysis using cerebrospinal fluid from narcolepsy type 1 patients publication-title: Sleep. doi: 10.1093/sleep/zsaa095 – volume: 32 start-page: 181 issue: 2 year: 2009 ident: 2022080922480599000_CIT0016 article-title: CSF histamine contents in narcolepsy, idiopathic hypersomnia and obstructive sleep apnea syndrome publication-title: Sleep. doi: 10.1093/sleep/32.2.181 – volume: 37 start-page: 1279 issue: 14 year: 1985 ident: 2022080922480599000_CIT0029 article-title: Correlations between aminergic metabolites simultaneously obtained from human CSF and brain publication-title: Life Sci. doi: 10.1016/0024-3205(85)90242-5 – volume: 9 start-page: 955 issue: 9 year: 2013 ident: 2022080922480599000_CIT0040 article-title: Disrupted nighttime sleep in narcolepsy publication-title: J Clin Sleep Med JCSM Off Publ Am Acad Sleep Med. – volume: 9 start-page: 246 issue: 1 Pt 2 year: 1986 ident: 2022080922480599000_CIT0012 article-title: Monoamine interactions in narcolepsy and hypersomnia: a preliminary report publication-title: Sleep. doi: 10.1093/sleep/9.1.246 – volume-title: ICSD-3: International Classification of Sleep Disorders year: 2014 ident: 2022080922480599000_CIT0025 – volume: 93 start-page: 747 issue: 4 year: 2017 ident: 2022080922480599000_CIT0028 article-title: Neural circuitry of wakefulness and sleep publication-title: Neuron. doi: 10.1016/j.neuron.2017.01.014 – volume: 35 start-page: 1359 issue: 10 year: 2012 ident: 2022080922480599000_CIT0014 article-title: Normal cerebrospinal fluid histamine and tele-methylhistamine levels in hypersomnia conditions publication-title: Sleep. doi: 10.5665/sleep.2114 – volume: 15 start-page: 269 issue: 4 year: 2011 ident: 2022080922480599000_CIT0037 article-title: Serotonin control of sleep–wake behavior publication-title: Sleep Med Rev. doi: 10.1016/j.smrv.2010.11.003 – volume: 6 start-page: 991 issue: 9 year: 2000 ident: 2022080922480599000_CIT0003 article-title: A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains publication-title: Nat Med. doi: 10.1038/79690 – volume: 32 start-page: 1299 issue: 11 year: 1982 ident: 2022080922480599000_CIT0010 article-title: Narcolepsy and idiopthic hypersomnia: biogenic amines and related compounds in CSF publication-title: Neurology. doi: 10.1212/WNL.32.11.1299 – ident: 2022080922480599000_CIT0024 article-title: The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications – volume: 54 start-page: 343 issue: 4 year: 2001 ident: 2022080922480599000_CIT0027 article-title: Adjusting for multiple testing–when and how? publication-title: J Clin Epidemiol. doi: 10.1016/S0895-4356(00)00314-0 – volume: 9 start-page: 789 issue: 8 year: 2013 ident: 2022080922480599000_CIT0042 article-title: Test–retest reliability of the multiple sleep latency test in narcolepsy without cataplexy and idiopathic hypersomnia publication-title: J Clin Sleep Med. doi: 10.5664/jcsm.2922 – volume: 40 start-page: zsx164 issue: 12 year: 2017 ident: 2022080922480599000_CIT0043 article-title: Test–retest reliability of the multiple sleep latency test in central disorders of hypersomnolence publication-title: Sleep. doi: 10.1093/sleep/zsx164 – volume: 14 start-page: 233 issue: 2 year: 2003 ident: 2022080922480599000_CIT0038 article-title: Altered rapid eye movement sleep timing in serotonin transporter knockout mice publication-title: Neuroreport. doi: 10.1097/00001756-200302100-00015 – volume: 98 start-page: 437 issue: 4 year: 1999 ident: 2022080922480599000_CIT0005 article-title: Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation publication-title: Cell. doi: 10.1016/S0092-8674(00)81973-X – volume: 80 start-page: 259 issue: 2 year: 2016 ident: 2022080922480599000_CIT0018 article-title: Absence of GABA-A receptor potentiation in central hypersomnolence disorders publication-title: Ann Neurol doi: 10.1002/ana.24710 – volume: 72 start-page: 934 issue: 11 year: 2012 ident: 2022080922480599000_CIT0021 article-title: Trace amine-associated receptor 1 partial agonism reveals novel paradigm for neuropsychiatric therapeutics publication-title: Biol Psychiatry. doi: 10.1016/j.biopsych.2012.05.014 – volume: 19 start-page: 620 issue: 4 year: 2010 ident: 2022080922480599000_CIT0013 article-title: Cerebrospinal fluid histamine levels are decreased in patients with narcolepsy and excessive daytime sleepiness of other origin publication-title: J Sleep Res. doi: 10.1111/j.1365-2869.2010.00819.x – volume: 92 start-page: 573 issue: 4 year: 1998 ident: 2022080922480599000_CIT0002 article-title: Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior publication-title: Cell. doi: 10.1016/S0092-8674(00)80949-6 – volume: 14 start-page: 540 issue: 6 year: 1991 ident: 2022080922480599000_CIT0023 article-title: A new method for measuring daytime sleepiness: the Epworth sleepiness scale publication-title: Sleep. doi: 10.1093/sleep/14.6.540 – volume: 44 start-page: 1485 issue: 8 year: 2019 ident: 2022080922480599000_CIT0034 article-title: Trace amine-associated receptor 1 agonism promotes wakefulness without impairment of cognition in Cynomolgus macaques publication-title: Neuropsychopharmacology. doi: 10.1038/s41386-019-0386-8 – volume: 30 start-page: 345 issue: 2 year: 2001 ident: 2022080922480599000_CIT0006 article-title: Genetic ablation of orexin neurons in mice results in narcolepsy, hypophagia, and obesity publication-title: Neuron. doi: 10.1016/S0896-6273(01)00293-8 – volume: 32 start-page: 175 issue: 2 year: 2009 ident: 2022080922480599000_CIT0017 article-title: Decreased CSF histamine in narcolepsy with and without low CSF hypocretin-1 in comparison to healthy controls publication-title: Sleep. doi: 10.1093/sleep/32.2.175 – volume: 20 start-page: 83 issue: 2 year: 2019 ident: 2022080922480599000_CIT0030 article-title: The neurobiological basis of narcolepsy publication-title: Nat Rev Neurosci. doi: 10.1038/s41583-018-0097-x – volume: 11 start-page: 567 issue: 10 year: 2015 ident: 2022080922480599000_CIT0031 article-title: Monoamine neurotransmitter disorders—clinical advances and future perspectives publication-title: Nat Rev Neurol. doi: 10.1038/nrneurol.2015.172 – volume: 42 start-page: 1305 issue: 6 year: 2017 ident: 2022080922480599000_CIT0033 article-title: Trace amine-associated receptor 1 regulates wakefulness and EEG spectral composition publication-title: Neuropsychopharmacology. doi: 10.1038/npp.2016.216 – volume: 95 start-page: 322 issue: 1 year: 1998 ident: 2022080922480599000_CIT0001 article-title: The hypocretins: hypothalamus-specific peptides with neuroexcitatory activity publication-title: Proc Natl Acad Sci USA. doi: 10.1073/pnas.95.1.322 – volume: 52 start-page: 101326 year: 2020 ident: 2022080922480599000_CIT0036 article-title: Reply to Maski K et al. commentary on diagnosis of central disorders of hypersomnolence: challenges in defining central disorders of hypersomnolence publication-title: Sleep Med Rev. doi: 10.1016/j.smrv.2020.101326 – volume: 83 start-page: 235 issue: 2 year: 2018 ident: 2022080922480599000_CIT0026 article-title: Alternative diagnostic criteria for idiopathic hypersomnia: a 32-hour protocol publication-title: Ann Neurol. doi: 10.1002/ana.25141 – volume: 18 start-page: 543 issue: 5 year: 2013 ident: 2022080922480599000_CIT0022 article-title: A new perspective for schizophrenia: TAAR1 agonists reveal antipsychotic- and antidepressant-like activity, improve cognition and control body weight publication-title: Mol Psychiatry. doi: 10.1038/mp.2012.57 – volume: 34 start-page: 6495 issue: 19 year: 2014 ident: 2022080922480599000_CIT0007 article-title: Conditional ablation of orexin/hypocretin neurons: a new mouse model for the study of narcolepsy and orexin system function publication-title: J Neurosci. doi: 10.1523/JNEUROSCI.0073-14.2014 – volume: 43 start-page: 23 year: 2019 ident: 2022080922480599000_CIT0039 article-title: Neurobiological and immunogenetic aspects of narcolepsy: implications for pharmacotherapy publication-title: Sleep Med Rev. doi: 10.1016/j.smrv.2018.09.006 |
| SSID | ssj0016493 |
| Score | 2.4631705 |
| Snippet | Abstract
Study Objectives
Whether the cause of daytime sleepiness in narcolepsy type 1 (NT1) is a direct consequence of the loss of orexin (ORX) neurons or... Whether the cause of daytime sleepiness in narcolepsy type 1 (NT1) is a direct consequence of the loss of orexin (ORX) neurons or whether low orexin reduces... Study Objectives: Whether the cause of daytime sleepiness in narcolepsy type 1 (NT1) is a direct consequence of the loss of orexin (ORX) neurons or whether low... Study Objectives Whether the cause of daytime sleepiness in narcolepsy type 1 (NT1) is a direct consequence of the loss of orexin (ORX) neurons or whether low... Abstract Study Objectives Whether the cause of daytime sleepiness in narcolepsy type 1 (NT1) is a direct consequence of the loss of orexin (ORX) neurons or... |
| SourceID | pubmedcentral hal proquest gale pubmed crossref oup |
| SourceType | Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 1 |
| SubjectTerms | Agricultural industry Amines Analysis Biogenic amines Biomarkers Cerebrospinal fluid Disorders of Excessive Somnolence Humans Idiopathic Hypersomnia Life Sciences Metabolites Narcolepsy Neurobiology Neurological Disorders Neurophysiology Neurosciences Orexins REM sleep Sleep Sleep disorders Wakefulness |
| Title | Cerebrospinal fluid monoamine levels in central disorders of hypersomnolence |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33476396 https://www.proquest.com/docview/2557239269 https://www.proquest.com/docview/2480275415 https://hal.science/hal-03665210 https://pubmed.ncbi.nlm.nih.gov/PMC8271127 |
| Volume | 44 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3db9MwELfY9sILYhsfgTIZhMYLUePEdZwnVPahAmNCiEl9ixx_qJXapCztJPjruUvcbJkEPKa-xhd_3e_s8-8Ieat1pi2L07BI0jjkgrlQ6SaHhnSx1FGWRngb-eulmFzxz9PR1G-41T6scrsmNgu1qTTukQ8B-qYxGHORfVj9DDFrFJ6u-hQaO2QPqcswpCuddg4XeAIt6S6gmlACkPAcm-DED-uFtavh71oVEYt7NsmvzDszDIzsXXq7gz3vh1DesUnnj8kjDybpuO39ffLAlgfkcFyCI738RY9pE97Z7JsfkosTew3-L6YJwf-4xWZuKHxUpZYANOkCg4dqOi-pr4saz8tZ08rRGbirAM2XZXtJ6Qm5Oj_7cTIJfSqFUANkWYeJZiKWJtLRaGSTgnOrhVFcGJMxpeHJuSJzvFDKOMuEAsNtrHFOZJYVWvHkKdktq9I-JxTFInDBdaYsl8wWYmSkVFIwUTjNTEDebxsz155nHNNdLPL2vDvJm7bPfdsH5LgTX7UEG38TfIc9k-PEg_dp5e8PgFZIYZWP8QRdSnCAAjLoScKE0b3iN9C3XWXIrz0ZX-T4G5hzAXgmumEBeQ1d_z-NBtuBkfuZX-e34xRe0RWjChjNVtpqAzJc4mkxYKeAPGvHUVdTknBY8jMRkLQ3wnr69kvK-azhBZdxCug5ffFvtV6ShzHG5TQhxwOyu77e2FcArNbFUTN7jsjex7PLb9_h6fTTlz8kOCkj |
| linkProvider | ProQuest |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3db9MwED9t3QO8IGB8BAoYBOOFqHHiOs4DQmVs6lhXIbRJewuOP9RKbVKWFjT-KP5GzklaFiTgaY-JHds63_l-F98HwEulEmVoGPtZFIc-49T6UlU1NIQNhQqSOHDRyCdjPjxjH8_751vwcx0L49wq12didVDrQrl_5D2EvnGIypwn7xZffVc1yt2urkto1GxxbC6_o8lWvj36gPv7KgwPD073h35TVcBXqL2XfqQoD4UOVNDvmyhjzCiuJeNaJ1QqfLI2SyzLpNTWUC5Rh2mjreWJoZmSLMJxt2GHRWjKdGDn_cH40-fNvQVndZpfxFG-QOjSZPUMkqhXzoxZ9H6UMgto2NKCjS7YnjhXzFaY3RW0-6fT5hUteHgbbjXwlQxqfrsDWya_C7uDHE33-SXZI5VDafWnfhdG--YCLW5XmMR9Y2erqSZIxkLOEdqSmXNXKsk0J81cRDeZQEtSWDJBAxmNgXleh0Xdg7NrIfN96ORFbh4Ccd0CNPpVIg0T1GS8r4WQglOeWUW1B2_WxExVk9ncFdiYpfUNe5RWtE8b2nuwt-m-qFN6_K3ja7czqRN1HE_JJmIBV-WSZqUDd2cvBJpcHnRbPVFEVav5Be7tZjKX0Xs4GKXuHQIIjggq-EY9eI5b_78VddeMkTZnTZn-lgwcYtPsluD853JTrLAPE-5-GtGaBw9qPtrMFEUMlUzCPYhbHNZab7sln06qTOQijBGvx4_-vaxncGN4ejJKR0fj48dwM3ReQZXDcxc6y4uVeYKwbpk9bWSJwJfrFt9fjb1olQ |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cerebrospinal+fluid+monoamine+levels+in+central+disorders+of+hypersomnolence&rft.jtitle=Sleep+%28New+York%2C+N.Y.%29&rft.au=Barateau%2C+Lucie&rft.au=Jaussent%2C+Isabelle&rft.au=Roeser%2C+Julien&rft.au=Ciardiello%2C+Claudio&rft.date=2021-07-01&rft.pub=Oxford+University+Press&rft.issn=0161-8105&rft.eissn=1550-9109&rft.volume=44&rft.issue=7&rft_id=info:doi/10.1093%2Fsleep%2Fzsab012 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0161-8105&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0161-8105&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0161-8105&client=summon |